9342-8530 Québec (OTCPK:DGCR.F) - Stock Price, News & Analysis

DGCR.F Stock Overview

9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. More details

DGCR.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap ($43)

Shares are highly illiquid

Latest financial reports are more than a year old

9342-8530 Québec Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$2.8k

MJ Holdings

OTCPK:MJNE

US$58.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Price History & Performance

Summary of all time highs, changes and price drops for 9342-8530 Québec
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-99.91%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	DGCR.F	US Biotechs	US Market
7D	0%	4.0%	2.0%
1Y	n/a	18.0%	32.4%

Return vs Industry: Insufficient data to determine how DGCR.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how DGCR.F performed against the US Market.

Price Volatility

Is DGCR.F's price volatile compared to industry and market?
DGCR.F volatility
DGCR.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: DGCR.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DGCR.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	n/a	Yves Fradet	www.diagnocure.com

9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test.

9342-8530 Québec Inc. Fundamentals Summary

How do 9342-8530 Québec's earnings and revenue compare to its market cap?
DGCR.F fundamental statistics
Market cap	US$43.00
Earnings (TTM)	US$1.99m
Revenue (TTM)	US$4.86m

0.0x

P/E Ratio

0.0x

P/S Ratio

Is DGCR.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DGCR.F income statement (TTM)
Revenue	CA$6.68m
Cost of Revenue	-CA$139.13k
Gross Profit	CA$6.82m
Other Expenses	CA$4.08m
Earnings	CA$2.74m

Last Reported Earnings

Jul 31, 2016

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did DGCR.F perform over the long term?

See historical performance and comparison